Scientists test if common drugs can stop an LSD trip
NCT ID NCT05964647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving ketanserin, olanzapine, or lorazepam after taking LSD can make the psychedelic effects shorter or weaker. Twenty healthy adults took LSD and then one of these drugs or a placebo. The goal was to see how the drugs changed the intensity and duration of the LSD experience.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LSD, ketanserin, olanzapine, lorazepam
- What this could lead to
- If successful, this could help develop ways to manage or shorten intense psychedelic experiences in therapeutic or emergency settings.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. Results may not apply to real-world use, and the drugs tested have their own side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
20 people
The number who actually took part.
- Started
-
Feb 2024
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 25 and 65 years 2. Sufficient understanding of the German language 3. Understanding of procedures and risks associated with the study 4. Willing to adhere to the protocol and signing of the consent form 5. Willing to refrain from the consumption of illicit psychoactive substances during the study 6. Abstaining from xanthine-based liquids and foods from the evenings prior to the study sessions to the end of the study days, limit coffee drinking ≤ 3 cups per day for 7 days prior to study day 7. Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration 8. Willing to use effective contraceptive measures throughout study participation (according to Clinical Trial Facilitation Group (CTFG): Recommendations related to contraception and pregnancy testing in clinical trials) 9. Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session. 10. Body mass index between 18 - 29 kg/m2 Exclusion Criteria: 1. Chronic or acute medical condition 2. Current or previous major psychiatric disorder including psychotic disorder, mania / hypomania, borderline personality disorders. 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Known hypersensitivity to LSD, ketanserin, olanzapine or lorazepam 5. Hypertension (\>140/90 mmHg) or hypotension (SBP \< 85 mmHg) 6. Hallucinogenic substance use (not including cannabis) more than 10 times or any time within the previous two months 7. Pregnancy or current breastfeeding 8. Participation in another clinical trial (currently or within the last 30 days) 9. Use of medication that may interfere with the effects of the study medication 10. Current substance use disorder (within the last 2 months) 11. Tobacco smoking (\>1 cigarette/day) 12. Consumption of alcoholic beverages (\>15 drinks/week) 13. Not exhibiting consistent startle responding on the screening day (i.e., over 75% discernible responses to six 108 dB 40 ms startle pulses), as this would preclude the ability to measure fear potentiated startle. 14. Use of strong CYP2D6 inhibitor 15. Use of strong CYP1A2 inhibitor or inducer
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Basel
Basel, Canton of Basel-City, 4055, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chewable postbiotic tablet keep plaque and gum inflammation at bay?
- Can a new oral drug safely help older adults manage weight?
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others